Please assess the completion status of the following clinical trial:

Trial Title: MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Part 1:~* healthy participants~* has a Body Mass Index (BMI) =\< 30 kg/m\^2~* female of reproductive potential remains abstinent or uses two acceptable methods of birth control from 2 weeks before first allergen challenge to 2 weeks after last allergen challenge; alternatively hormonal contraception may be used.~Part 2:~* has a Body Mass Index (BMI) =\< 38 kg/m\^2~* has a clinical history of allergic rhinitis/rhinoconjunctivitis to HDM for at least one year, and used medication to relieve symptoms within the last year~* does not have asthma, or has mild controlled asthma not requiring regular use over the 12 months prior to screening of any corticosteroids~* female of reproductive potential remains abstinent or use two acceptable methods of birth control from 2 weeks before first allergen challenge to at least 2 weeks after last allergen challenge or last dose of study drug, whichever is longer~* has not smoked or used tobacco for the prior 6 months, and agrees not to during study~Exclusion Criteria:~Parts 1 and 2:~* is experiencing at the first NAC visit, symptoms from an upper or lower respiratory tract infection (viral or bacterial)~* has participated within the prior 3 months in another investigational study (that included an investigational drug or agent)~* is directly associated with the administration of the study or is related to the investigational study staff~* is mentally or legally incapacitated, has significant emotional problems or has a history of clinically significant psychiatric disorder within the past 5 years~* has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological (including stroke and chronic seizures) abnormalities or diseases~* has a history of cancer~* has a history of significant intolerability to drugs or food~* is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV~* had major surgery or lost 1 unit (500 mL) of blood within the prior 4 weeks~* has a clinical history of chronic sinusitis during the prior 2 years~* has any nasal condition (e.g. nasal polyposis) that could confound efficacy or safety assessments~* is pregnant or expects to conceive during the study period~* is a nursing mother~* consumes more than 3 glasses of alcoholic beverages per day~* regularly uses any illicit drug, or has a history of drug or alcohol abuse within the prior 6 months~Part 2 only:~* is experiencing allergic rhinoconjunctivitis exacerbation at Screening NAC~* consumes excessive daily amounts of caffeinated beverages~* has a known history of allergy, hypersensitivity or intolerance to investigational medicines~* is sensitized and regularly exposed to animal dander and molds in the home or workplace in a manner that might interfere with the study in the opinion of the investigator~* is sensitized and regularly exposed to seasonal allergens such as Birch or grass pollen (sensitized but out of season is acceptable however)~* has a history of chronic urticaria and/or angioedema within the prior 2 years~* has had previous immunotherapeutic treatment with any HDM allergen for more than 1 month during the prior 3 years~* is receiving any specific immunotherapy within prior 60 days~* has a history of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy due to an unknown cause or an inhalant allergen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- NAC + MK-8237 (Part 2) (Type: EXPERIMENTAL): Nasal Allergen Challenge (NAC) treatment consisting of 1800 Biological Units (BU) of HDM extract on Days -14, 56 and 84; starting on Day 1 a single tablet of MK-8237 with 12 Development Units (DUs), administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
- NAC + Placebo (Part 2) (Type: PLACEBO_COMPARATOR): NAC treatment consisting of 1800 BU of HDM extract on Days -14, 56 and 84; starting on Day 1 a single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
- NAC (Part 1) (Type: EXPERIMENTAL): Nasal Allergen Challenge (NAC) consisting of 100 µl fixed volume of 10,000 biological units (BU) of HDM extract delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1

Based on this trial design, predict the completion outcome and termination type (if applicable).